Now showing items 1751-1770 of 3070

    • Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy. 

      Haynes, BP; Ginsburg, O; Gao, Q; Folkerd, E; Afentakis, M; Quang, LH; Han, PT; Khoa, PH; Dinh, NV; To, TV; Clemons, M; Smith, IE; Dowsett, M (2017)
      For premenopausal women with primary ER + breast cancer, oophorectomy (OvX) is an evidence-based cost-effective option and is standard treatment in many countries. However, there is virtually no data describing the effects ...
    • Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. 

      Lopez-Knowles, E; Pearson, A; Schuster, G; Gellert, P; Ribas, R; Yeo, B; Cutts, R; Buus, R; Garcia-Murillas, I; Haynes, B; Martin, L-A; Smith, I; Turner, N; Dowsett, M (2019-01)
      BACKGROUND: Several thousand breast cancer patients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease. MATERIALS ...
    • Molecular complexities of stem cells 

      Joshi, C; Enver, T (2003-05)
      Stem cells continue to attract considerable attention and provide hope for the development of new cell-based therapies for degenerative diseases. Unlocking the full therapeutic potential of stem cells requires an understanding ...
    • Molecular cytogenetic analysis consistently identifies translocations involving chromosomes 1, 2 and 15 in five embryonal rhabdomyosarcoma cell lines and a PAX-FOXO1A fusion gene negative alveolar rhabdomyosarcoma cell line. 

      Roberts, I; Gordon, A; Wang, R; Pritchard-Jones, K; Shipley, J; Coleman, N (2001-01)
      Rhabdomyosarcoma in children is a "small round blue cell tumour" that displays skeletal muscle differentiation. Two main histological variants are recognised, alveolar (ARMS) and embryonal (ERMS) rhabdomyosarcoma. Whereas ...
    • Molecular cytogenetic study of a mantle cell lymphoma with a complex translocation involving the CCND1 (11q13) region 

      Maravelaki, S; Burford, A; Wotherspoon, A; Joshi, R; Matutes, E; Catovsky, D; Brito-Babapulle, V (2004)
      We describe a progressive mantle cell lymphoma (MCL) in which multicolor fluorescence in situ hybridization (M-FISH) on metaphases did not detect the characteristic t(11;14)(q13;q32), although translocations of chromosomes ...
    • Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer 

      Lakhani, SR (2001-10)
      Breast cancer is a common solid malignancy in women. Over the past decade, much progress has been made in understanding the biology of breast cancer. The use of molecular and immunohistochemical techniques is providing ...
    • The molecular landscape of colitis-associated carcinogenesis. 

      Saraggi, D; Fassan, M; Mescoli, C; Scarpa, M; Valeri, N; Michielan, A; D'Incá, R; Rugge, M (2017-04)
      In spite of the well-established histopathological phenotyping of IBD-associated preneoplastic and neoplastic lesions, their molecular landscape remains to be fully elucidated. Several studies have pinpointed the initiating ...
    • Molecular mechanisms of Bdp1 in TFIIIB assembly and RNA polymerase III transcription initiation. 

      Gouge, J; Guthertz, N; Kramm, K; Dergai, O; Abascal-Palacios, G; Satia, K; Cousin, P; Hernandez, N; Grohmann, D; Vannini, A (2017-07-25)
      Initiation of gene transcription by RNA polymerase (Pol) III requires the activity of TFIIIB, a complex formed by Brf1 (or Brf2), TBP (TATA-binding protein), and Bdp1. TFIIIB is required for recruitment of Pol III and to ...
    • Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. 

      Galluzzi, L; Vitale, I; Aaronson, SA; Abrams, JM; Adam, D; Agostinis, P; Alnemri, ES; Altucci, L; Amelio, I; Andrews, DW; Annicchiarico-Petruzzelli, M; Antonov, AV; Arama, E; Baehrecke, EH; Barlev, NA; Bazan, NG; Bernassola, F; Bertrand, MJM; Bianchi, K; Blagosklonny, MV; Blomgren, K; Borner, C; Boya, P; Brenner, C; Campanella, M; Candi, E; Carmona-Gutierrez, D; Cecconi, F; Chan, FK-M; Chandel, NS; Cheng, EH; Chipuk, JE; Cidlowski, JA; Ciechanover, A; Cohen, GM; Conrad, M; Cubillos-Ruiz, JR; Czabotar, PE; D'Angiolella, V; Dawson, TM; Dawson, VL; De Laurenzi, V; De Maria, R; Debatin, K-M; DeBerardinis, RJ; Deshmukh, M; Di Daniele, N; Di Virgilio, F; Dixit, VM; Dixon, SJ; Duckett, CS; Dynlacht, BD; El-Deiry, WS; Elrod, JW; Fimia, GM; Fulda, S; García-Sáez, AJ; Garg, AD; Garrido, C; Gavathiotis, E; Golstein, P; Gottlieb, E; Green, DR; Greene, LA; Gronemeyer, H; Gross, A; Hajnoczky, G; Hardwick, JM; Harris, IS; Hengartner, MO; Hetz, C; Ichijo, H; Jäättelä, M; Joseph, B; Jost, PJ; Juin, PP; Kaiser, WJ; Karin, M; Kaufmann, T; Kepp, O; Kimchi, A; Kitsis, RN; Klionsky, DJ; Knight, RA; Kumar, S; Lee, SW; Lemasters, JJ; Levine, B; Linkermann, A; Lipton, SA; Lockshin, RA; López-Otín, C; Lowe, SW; Luedde, T; Lugli, E; MacFarlane, M; Madeo, F; Malewicz, M; Malorni, W; Manic, G; Marine, J-C; Martin, SJ; Martinou, J-C; Medema, JP; Mehlen, P; Meier, P; Melino, S; Miao, EA; Molkentin, JD; Moll, UM; Muñoz-Pinedo, C; Nagata, S; Nuñez, G; Oberst, A; Oren, M; Overholtzer, M; Pagano, M; Panaretakis, T; Pasparakis, M; Penninger, JM; Pereira, DM; Pervaiz, S; Peter, ME; Piacentini, M; Pinton, P; Prehn, JHM; Puthalakath, H; Rabinovich, GA; Rehm, M; Rizzuto, R; Rodrigues, CMP; Rubinsztein, DC; Rudel, T; Ryan, KM; Sayan, E; Scorrano, L; Shao, F; Shi, Y; Silke, J; Simon, H-U; Sistigu, A; Stockwell, BR; Strasser, A; Szabadkai, G; Tait, SWG; Tang, D; Tavernarakis, N; Thorburn, A; Tsujimoto, Y; Turk, B; Vanden Berghe, T; Vandenabeele, P; Vander Heiden, MG; Villunger, A; Virgin, HW; Vousden, KH; Vucic, D; Wagner, EF; Walczak, H; Wallach, D; Wang, Y; Wells, JA; Wood, W; Yuan, J; Zakeri, Z; Zhivotovsky, B; Zitvogel, L; Melino, G; Kroemer, G (2018-03)
      Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives. Since the ...
    • Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes? 

      Eason, K; Sadanandam, A (2016-09)
      Tumor heterogeneity is reflected and influenced by genetic, epigenetic, and metabolic differences in cancer cells and their interactions with a complex microenvironment. This heterogeneity has resulted in the stratification ...
    • Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor. 

      Whittaker, SR; Barlow, C; Martin, MP; Mancusi, C; Wagner, S; Self, A; Barrie, E; Te Poele, R; Sharp, S; Brown, N; Wilson, S; Jackson, W; Fischer, PM; Clarke, PA; Walton, MI; McDonald, E; Blagg, J; Noble, M; Garrett, MD; Workman, P (2018-03)
      Deregulation of the cyclin-dependent kinases (CDKs) has been implicated in the pathogenesis of multiple cancer types. Consequently, CDKs have garnered intense interest as therapeutic targets for the treatment of cancer. ...
    • Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. 

      Moorcraft, SY; Jones, T; Walker, BA; Ladas, G; Kalaitzaki, E; Yuan, L; Begum, R; Eltahir, Z; Wotherspoon, A; Montero-Fernandez, A; Teixeira Mendes, LS; Gonzalez de Castro, D; Wilson, SH; Proszek, P; To, YM; Hawkes, E; Roy, A; Cunningham, D; Rao, S; Watkins, D; Starling, N; Bowcock, AM; Chau, I (2017-09-12)
      This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed ...
    • Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. 

      Moorcraft, SY; Jones, T; Walker, BA; Ladas, G; Kalaitzaki, E; Yuan, L; Begum, R; Eltahir, Z; Wotherspoon, A; Montero-Fernandez, A; Teixeira Mendes, LS; Gonzalez de Castro, D; Hulkki Wilson, S; Proszek, P; To, YM; Hawkes, E; Roy, A; Cunningham, D; Rao, S; Watkins, D; Starling, N; Bowcock, AM; Chau, I (2017-04-11)
      This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed ...
    • Molecular radiotheragnostics in prostate cancer 

      Du, Y; Dizdarevic, S (Royal College of Physicians, 2017-10)
    • Molecular radiotheranostics for neuroendocrine tumours. 

      Navalkissoor, S; Flux, G; Bomanji, J (2017-10)
      This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus ...
    • Molecular signatures of self-renewal, differentiation, and lineage choice in multipotential hemopoietic progenitor cells in vitro 

      Bruno, L; Hoffmann, R; McBlane, F; Brown, J; Gupta, R; Joshi, C; Pearson, S; Seidl, T; Heyworth, C; Enver, T (2004-01)
      The molecular mechanisms governing self-renewal, differentiation, and lineage specification remain unknown. Transcriptional profiling is likely to provide insight into these processes but, as yet, has been confined to ...
    • Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. 

      Szucs, Z; Thway, K; Fisher, C; Bulusu, R; Constantinidou, A; Benson, C; van der Graaf, WT; Jones, RL (2016-09-07)
      Gastrointestinal stromal tumors (GISTs) are composed of various molecular subtypes, with differing prognostic and predictive relevance. Previously, tumors lacking mutations in the KIT and PDGFRA genes have been designated ...
    • The molecular underpinnings of prostate cancer: impacts on management and pathology practice. 

      Rodrigues, DN; Boysen, G; Sumanasuriya, S; Seed, G; Marzo, AMD; de Bono, J (2017-01)
      Prostate cancer (PCa) is a clinically heterogeneous disease and current treatment strategies are based largely on anatomical and pathological parameters. In the recent past, several DNA sequencing studies of primary and ...
    • Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. 

      Mackay, A; Burford, A; Molinari, V; Jones, DTW; Izquierdo, E; Brouwer-Visser, J; Giangaspero, F; Haberler, C; Pietsch, T; Jacques, TS; Figarella-Branger, D; Rodriguez, D; Morgan, PS; Raman, P; Waanders, AJ; Resnick, AC; Massimino, M; Garrè, ML; Smith, H; Capper, D; Pfister, SM; Würdinger, T; Tam, R; Garcia, J; Thakur, MD; Vassal, G; Grill, J; Jaspan, T; Varlet, P; Jones, C (2018-05-14)
      The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between ...
    • Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. 

      Lheureux, S; Denoyelle, C; Ohashi, PS; De Bono, JS; Mottaghy, FM (2017-08)
      Molecular imaging continues to influence every aspect of cancer care including detection, diagnosis, staging and therapy response assessment. Recent advances in the understanding of cancer biology have prompted the ...